Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Healthy Children 12 to 15 Months of Age

Trial Profile

Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Healthy Children 12 to 15 Months of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Hepatitis A vaccine inactivated; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Varicella zoster virus vaccine live
  • Indications Hepatitis A; Measles; Mumps; Pneumococcal infections; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 09 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top